← FDA DRUG APPROVALS

FDA NDA · NDA019174

TRANDATE HCT

Sponsor: GLAXOSMITHKLINE

APPLICATION
NDA019174
TYPE
NDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

TRANDATE HCTDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LABETALOL HYDROCHLORIDE 300MG · TABLET · ORAL
TRANDATE HCTDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LABETALOL HYDROCHLORIDE 100MG · TABLET · ORAL
TRANDATE HCTDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LABETALOL HYDROCHLORIDE 400MG · TABLET · ORAL
TRANDATE HCTDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LABETALOL HYDROCHLORIDE 200MG · TABLET · ORAL
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →